Sarepta Therapeutics (NASDAQ:SRPT) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Tuesday,Benzinga reports. The brokerage currently has a $202.00 price target on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Scotiabank started coverage on shares of Sarepta Therapeutics in a report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 price target on the stock. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Royal Bank of Canada decreased their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $170.23.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $73.54 on Tuesday. Sarepta Therapeutics has a one year low of $73.06 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $7.14 billion, a price-to-earnings ratio of 58.83 and a beta of 0.79. The firm’s fifty day moving average is $110.18 and its two-hundred day moving average is $119.13.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its holdings in Sarepta Therapeutics by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock valued at $75,842,000 after acquiring an additional 12,000 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after buying an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC grew its stake in shares of Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after buying an additional 116,800 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $3,829,000. Finally, Larson Financial Group LLC grew its stake in shares of Sarepta Therapeutics by 1,649.8% in the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after buying an additional 8,249 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.